FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORT

Key Points

• FAS Wealth Partners increased its Corcept Therapeutics stake by 4% in the first quarter to 322,370 shares, worth approximately $13.0 million. Institutional investors collectively own 93.61% of the company.
• Corcept reported stronger-than-expected quarterly results, with EPS of $0.36 versus the $0.02 consensus estimate and revenue of $256.15 million, up 31.7% year over year.
• Analyst sentiment is mixed: the consensus rating is “Moderate Buy,” but insider selling totaled 300,000 shares worth $22.1 million over the past 90 days, while the stock trades at a high price-to-earnings ratio of 272.6.

FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 322,370 shares of the biotechnology company's stock after buying an additional 12,352 shares during the quarter. FAS Wealth Partners Inc. owned about 0.30% of Corcept Therapeutics worth $12,995,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in shares of Corcept Therapeutics in the third quarter valued at $25,000. Larson Financial Group LLC boosted its stake in shares of Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 442 shares during the period. Gould Capital LLC boosted its stake in shares of Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 200 shares during the period. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth about $25,000. Finally, CIBC Private Wealth Group LLC grew its holdings in Corcept Therapeutics by 128.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 433 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Atabak Mokari sold 40,000 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $81.15, for a total value of $3,246,000.00. Following the completion of the sale, the chief financial officer owned 16,130 shares in the company, valued at approximately $1,308,949.50. The trade was a 71.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David L. Mahoney sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total value of $1,690,600.00. Following the completion of the transaction, the director directly owned 26,147 shares in the company, valued at approximately $2,210,205.91. This trade represents a 43.34% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 300,000 shares of company stock valued at $22,088,050. Insiders own 20.70% of the company's stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept’s latest quarterly results exceeded expectations, with earnings of $0.36 per share versus the $0.02 consensus estimate and revenue of $256.15 million versus $221.15 million expected. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler assigned Corcept an “Overweight” rating, signaling confidence in the company’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $165 price target. The firm raised its FY2026 EPS forecast to $2.15 from $0.80 and increased its Q3 2026 estimate to $0.78 from $0.34, suggesting expectations for significant near-term earnings growth.
• Neutral Sentiment: Brokerages’ average target price is $94.67, materially below the recent $114.49 reference price. This gap indicates analysts have not fully caught up with the rally or see limited upside from current levels. Brokerages Set Corcept Therapeutics Target Price at $94.67
• Negative Sentiment: Despite the bullish rating, HC Wainwright reduced its FY2027 EPS forecast to $3.95 from $5.38 and lowered estimates for Q1–Q4 2027. These revisions raise concerns about the pace of longer-term earnings growth, particularly with CORT trading at a very high valuation.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CORT shares. Piper Sandler reissued an "overweight" rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday. Wolfe Research cut Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $50.00 target price on the stock. in a research note on Monday, July 27th. Truist Financial upgraded Corcept Therapeutics to a "strong-buy" rating in a report on Monday, June 15th. HC Wainwright raised their price target on Corcept Therapeutics from $95.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Wall Street Zen raised Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $119.17.

Corcept Therapeutics Price Performance

Shares of CORT opened at $114.49 on Monday. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $122.21. The company has a 50-day moving average of $84.77 and a 200 day moving average of $56.91. The firm has a market capitalization of $12.38 billion, a price-to-earnings ratio of 272.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analysts' expectations of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm's quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.29 EPS. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current fiscal year.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.